Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Decoupling FcRn and tumor contributions to elevated immune checkpoint inhibitor clearance in cancer cachexia

Published:2024-01 Issue: Volume:199 Page:107048
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Vu Trang T.,Kim Kyeongmin,Manna Millennium,Thomas Justin,Remaily Bryan C.,Montgomery Emma J.,Costa Travis,Granchie Lauren,Xie Zhiliang,Guo Yizhen,Chen Min,Castillo Alyssa Marie M.,Kulp Samuel K.,Mo Xiaokui,Nimmagadda Sridhar,Gregorevic Paul,Owen Dwight H.,Ganesan Latha P.,Mace Thomas A.,Coss Christopher C.,Phelps Mitch A.

Publisher

Elsevier BV

Subject

Pharmacology

Reference112 articles.

1. Immunotherapy for the first-line treatment of patients with metastatic non-small cell lung cancer;Martinez;Clin. Cancer Res,2019

2. Immunotherapy in the frontline management of advanced and metastatic NSCLC;Segal;Am. J. Manag Care,2021

3. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer;Reck;N. Engl. J. Med,2016

4. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer;Gandhi;N. Engl. J. Med,2018

5. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer;Antonia;N. Engl. J. Med,2017

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP